Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers

S. Y. Park; J. S. Lee; J. S. Son; J. H. Ko; K. R. Peck; Y. Jung; H. J. Woo; Y. S. Joo; J. S. Eom; H. Shi

doi:10.1016/j.jhin.2018.09.005

Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers

S. Y. Park
, J. S. Lee
, J. S. Son
, J. H. Ko
, K. R. Peck
, Y. Jung
, H. J. Woo
, Y. S. Joo
, J. S. Eom
, H. Shi

Research output: Contribution to journal › Article › peer-review

68 Citations (Scopus)

Abstract

An effective post-exposure prophylaxis (PEP) strategy may limit the spread of infection. However, there is no consensus regarding PEP for Middle East respiratory syndrome coronavirus (MERS-CoV) infection. This study assessed the efficacy of ribavirin and lopinavir/ritonavir as PEP for healthcare workers (HCWs) exposed to patients with severe MERS-CoV pre-isolation pneumonia. The safety of the PEP regimen was assessed. HCWs with high-risk exposure to MERS-CoV pre-isolation pneumonia were retrospectively enrolled. HCWs who received PEP therapy were classified into the PEP group. PEP therapy was associated with a 40% decrease in the risk of infection. There were no severe adverse events during PEP therapy.

Original language	English
Pages (from-to)	42-46
Number of pages	5
Journal	Journal of Hospital Infection
Volume	101
Issue number	1
DOIs	https://doi.org/10.1016/j.jhin.2018.09.005
Publication status	Published - Jan 2019

Bibliographical note

Publisher Copyright:
© 2018 The Healthcare Infection Society

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Healthcare worker
High-risk exposure
Middle East respiratory syndrome coronavirus
Outbreak
Post-exposure prophylaxis
Pre-isolation pneumonia

Access to Document

10.1016/j.jhin.2018.09.005

Cite this

@article{680b70ca2c0d4bd28c5ef0da64fbbbbc,

title = "Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers",

abstract = "An effective post-exposure prophylaxis (PEP) strategy may limit the spread of infection. However, there is no consensus regarding PEP for Middle East respiratory syndrome coronavirus (MERS-CoV) infection. This study assessed the efficacy of ribavirin and lopinavir/ritonavir as PEP for healthcare workers (HCWs) exposed to patients with severe MERS-CoV pre-isolation pneumonia. The safety of the PEP regimen was assessed. HCWs with high-risk exposure to MERS-CoV pre-isolation pneumonia were retrospectively enrolled. HCWs who received PEP therapy were classified into the PEP group. PEP therapy was associated with a 40\% decrease in the risk of infection. There were no severe adverse events during PEP therapy.",

keywords = "Healthcare worker, High-risk exposure, Middle East respiratory syndrome coronavirus, Outbreak, Post-exposure prophylaxis, Pre-isolation pneumonia",

author = "Park, \{S. Y.\} and Lee, \{J. S.\} and Son, \{J. S.\} and Ko, \{J. H.\} and Peck, \{K. R.\} and Y. Jung and Woo, \{H. J.\} and Joo, \{Y. S.\} and Eom, \{J. S.\} and H. Shi",

note = "Publisher Copyright: {\textcopyright} 2018 The Healthcare Infection Society",

year = "2019",

month = jan,

doi = "10.1016/j.jhin.2018.09.005",

language = "English",

volume = "101",

pages = "42--46",

journal = "Journal of Hospital Infection",

issn = "0195-6701",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers

AU - Park, S. Y.

AU - Lee, J. S.

AU - Son, J. S.

AU - Ko, J. H.

AU - Peck, K. R.

AU - Jung, Y.

AU - Woo, H. J.

AU - Joo, Y. S.

AU - Eom, J. S.

AU - Shi, H.

PY - 2019/1

Y1 - 2019/1

N2 - An effective post-exposure prophylaxis (PEP) strategy may limit the spread of infection. However, there is no consensus regarding PEP for Middle East respiratory syndrome coronavirus (MERS-CoV) infection. This study assessed the efficacy of ribavirin and lopinavir/ritonavir as PEP for healthcare workers (HCWs) exposed to patients with severe MERS-CoV pre-isolation pneumonia. The safety of the PEP regimen was assessed. HCWs with high-risk exposure to MERS-CoV pre-isolation pneumonia were retrospectively enrolled. HCWs who received PEP therapy were classified into the PEP group. PEP therapy was associated with a 40% decrease in the risk of infection. There were no severe adverse events during PEP therapy.

AB - An effective post-exposure prophylaxis (PEP) strategy may limit the spread of infection. However, there is no consensus regarding PEP for Middle East respiratory syndrome coronavirus (MERS-CoV) infection. This study assessed the efficacy of ribavirin and lopinavir/ritonavir as PEP for healthcare workers (HCWs) exposed to patients with severe MERS-CoV pre-isolation pneumonia. The safety of the PEP regimen was assessed. HCWs with high-risk exposure to MERS-CoV pre-isolation pneumonia were retrospectively enrolled. HCWs who received PEP therapy were classified into the PEP group. PEP therapy was associated with a 40% decrease in the risk of infection. There were no severe adverse events during PEP therapy.

KW - Healthcare worker

KW - High-risk exposure

KW - Middle East respiratory syndrome coronavirus

KW - Outbreak

KW - Post-exposure prophylaxis

KW - Pre-isolation pneumonia

UR - https://www.scopus.com/pages/publications/85056156511

U2 - 10.1016/j.jhin.2018.09.005

DO - 10.1016/j.jhin.2018.09.005

M3 - Article

C2 - 30240813

AN - SCOPUS:85056156511

SN - 0195-6701

VL - 101

SP - 42

EP - 46

JO - Journal of Hospital Infection

JF - Journal of Hospital Infection

IS - 1

ER -

Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this